Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of DS-3939a in advanced solid tumors
CTR20252034Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DS-3939 in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
DS-3939
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252034.